Dr. Koestler is an executive director, of Vatera Holdings. In addition to being the chairman of the board of directors of Melinta Therapeutics, Dr. Koestler is a member of the boards of directors of ImmusanT, Inc., Novo Nordisk A/S, Momenta Pharmaceuticals Inc., Arisaph Pharmaceuticals Inc., Edgemont Pharmaceuticals, LLC, and ReSearch Pharmaceutical Services (recently sold to KKR).
In his nearly 30-year career in the pharmaceutical industry, Dr. Koestler established a track record of building high-performance teams that drove global success in research and development. Most recently he served as executive vice president of Schering Corporation and president of Schering-Plough Research Institute (SPRI), the pharmaceutical research and development arm of Schering-Plough Corporation. Under his leadership, the company developed an industry-leading pipeline that contributed to the turnaround of the business. Dr. Koestler’s accomplishments include over 80 product approvals including over 30 New Molecular Entities/BLAs.
Before joining Schering-Plough, he was senior vice president and head of global regulatory affairs for Pharmacia Corporation. Prior to joining Pharmacia, Dr. Koestler was senior vice president and global head, drug regulatory affairs, compliance assurance, clinical safety and epidemiology for Novartis. Before that appointment, he was senior director, drug regulatory affairs, at Ortho McNeil and Director of Regulatory Affairs at Bristol-Myers Squibb, Westwood Pharmaceuticals.
Dr. Koestler earned his B.S. in biology from Daemen College and a Ph.D. in medicine & pathology from the Roswell Park Memorial Institute.